The MLR review process is the sign-off every piece of promotional material must clear before a pharma, biotech or medical device company puts it in front of a customer. Medical checks that the science is accurate and fairly presented. Legal checks that every claim can be defended. Regulatory checks that the material matches the product's approved or cleared labeling. Nothing reaches a rep, a website or a trade show booth until all three agree.
Most teams blame the review itself when approved content is slow to reach the field. Usually only part of that is fair. The delay builds up in two places: in the queue before review, and in the gap after approval, when an approved PDF still has to travel from the review system to 140 reps' tablets. This post covers both.
What is medical legal regulatory review?
Medical legal regulatory review (usually shortened to MLR, and in some companies called PRC, for promotional review committee) is a standing cross-functional review of anything that promotes a product. That covers detail aids, slide decks, sell sheets, emails, web pages, social posts, booth graphics, videos, and increasingly the talk tracks and AI-generated summaries reps use.
The three reviewers each own a different question:
- Medical (medical affairs or clinical): Is this scientifically accurate? Does each claim trace to a reference that actually supports it, with the study population and endpoints described fairly?
- Legal: Could a competitor, a regulator or a plaintiff's attorney challenge this claim? Are comparative claims substantiated? Are trademarks, disclaimers and fair-balance language right?
- Regulatory: Is this consistent with the approved or cleared indication? Does it include required safety information? Does it need to be filed with the agency?
A review coordinator runs the queue, and the brand or marketing owner submits the piece and answers comments. Many teams add compliance, and some add a market access or health economics reviewer for payer-facing material.
Why does MLR review exist at all?
Because in a regulated industry, what a rep shows a customer is the company's legal statement about its product.
For prescription drugs, the rule is explicit. Under 21 CFR 314.81(b)(3)(i), a company must submit its advertising and promotional labeling to FDA on Form FDA-2253 at the time of initial dissemination or publication. For medical devices, FDA's general controls require restricted-device advertising to carry the device's established name, a brief statement of its intended uses, and relevant warnings, precautions, side effects and contraindications. A restricted device with false or misleading advertising is considered misbranded.
For the field team, that has one practical meaning: an off-label claim in a rep's deck, or a retired claim in a customer's inbox, belongs to the company. MLR is how the company decides in advance what it is willing to own. That is why sales enablement for life sciences is less about producing more content and more about making sure the approved version is the only version reps can reach.
What are the steps in the MLR review process?
The details vary by company, but the sequence is close to universal:
- Brief and intake. The marketer defines the audience, channel and key claims, and checks whether an approved piece already covers the need.
- Draft with references. Every claim gets annotated with the specific page and passage in the reference that supports it.
- Submission. The piece goes into your MLR or review system with metadata: product, audience, channel, intended use, and a proposed expiration date.
- Review rounds. Medical, legal and regulatory comment, sometimes in parallel and sometimes in sequence.
- Revise and resubmit. The owner resolves comments. Reviewers check the changes, and this step loops.
- Approval. The piece gets a job code (a tracking number), an approval date and an expiration or re-review date.
- Distribution. The approved file goes to the channel: the website, the email platform, and the field.
- Maintenance. Expiration, periodic re-review, and withdrawal when a label changes, a study is superseded or a claim is retired.
Steps 1 through 6 happen where reviewers can see them. Steps 7 and 8 usually don't, and that is where most of the field-facing delay and risk sits.
Where does the MLR review process bottleneck?
Submissions that arrive unready
A piece submitted with half its claims unreferenced costs a full review round. Reviewers can't approve what they can't verify. They send it back, and the piece loses a week. The fix sits upstream: a submission checklist, and a coordinator who sends back incomplete work before it reaches the reviewers.
Everything reviewed at the same depth
A webinar invitation and a comparative clinical claims deck should not wait in the same line. Teams that sort submissions by risk (new claims, existing approved claims in a new format, and administrative changes) keep their senior reviewers on the pieces that need them.
Rounds that never converge
When comments arrive one reviewer at a time, or two reviewers disagree in the margins, a piece can cycle for weeks. A short live review meeting often resolves in thirty minutes what three asynchronous rounds did not.
Approval that never reaches the field
This is the bottleneck nobody measures. The piece is approved and sitting in the review system. Marketing downloads it, emails it to the regional managers, and posts it to a shared drive. Reps save a copy to their desktops. Three months later it expires or gets withdrawn. The review system knows. The rep's tablet does not.
From the field's point of view, approval took as long as it took to reach them. A clean four-week review followed by a three-week manual rollout is a seven-week review.
An MLR bottleneck diagnostic
Use this to work out where your delay actually lives before you try to speed up the reviewers.
| Symptom | Where it is really stuck | What fixes it |
|---|---|---|
| Most pieces need three or more rounds | Intake: claims arrive unreferenced or unclear | Submission checklist; coordinator returns incomplete submissions before review |
| Simple updates wait as long as new campaigns | Triage: one queue for every risk level | Risk tiers with different reviewer paths and service levels |
| Reviewers keep re-approving the same claims | Reuse: no library of pre-approved claims | Approved claims and modular blocks that new pieces can assemble from |
| Reps ask marketing for a file that is already approved | Findability: the approved version isn't where reps look | One field library, searchable, synced to devices |
| A new version is approved but reps still show the old one | Distribution: files reach reps as email attachments and downloads | Replace-in-place versioning that updates every device, including offline ones |
| Nobody can say which reps still hold a withdrawn piece | Maintenance: expiration doesn't travel with the file | Approval status and expiry synced from the review system, with withdrawn items hidden automatically |
| Reps build their own slides to fill gaps | Coverage: field needs never reach the content plan | Track what reps search for and can't find, and feed it into the next brief |
Rows one to three belong to the review team. Rows four to seven belong to whoever owns field enablement, and in most companies nobody owns them explicitly.
How do you get MLR-approved content to reps faster?
Treat approval as the start of distribution, not the end of the job. In practice, that means five things.
1. Connect the review system to the field library. The approved file, its job code and its expiration date should flow from your MLR system into the library reps use, on a schedule, without anyone downloading and re-uploading. Every manual hand-off is a place where the wrong version can slip in. SoloFire does this through integrations with regulated content systems: approved files sync into mapped folders every 15 minutes, carry an approved, expired or withdrawn badge, and withdrawn items are hidden from reps automatically.
2. Replace files; don't add new ones. When a piece is revised, the new version should take the old one's place everywhere at once, including on devices that are offline in a hospital basement. That is the core of version control for sales content. If "v3_FINAL_approved" and "v4" can sit side by side, reps will pick the wrong one.
3. Make expiration travel with the file. The expiration date agreed in review should be enforced in the field, not tracked in a spreadsheet. The same applies to access: a piece approved only for hospital-based specialists shouldn't be visible to the whole sales force. That is what role-based content access is for.
4. Share links, not attachments. An attachment freezes the version on the day you sent it. A tracked link can show the current version and stop showing a withdrawn one. It also gives you a record of exactly what each customer received.
5. Keep AI inside the approved library. Reps now ask AI tools questions about products. If the assistant answers from the open web, it can produce claims MLR never saw. An assistant grounded only in approved content, like Spark AI, which cites the approved file behind each answer, keeps AI answers inside the same approved boundary as everything else.
For the governance basics underneath all of this, see keeping content approved and current for med device reps.
What good looks like
A label update comes through on a Tuesday. Regulatory withdraws the old detail aid in the review system that afternoon and approves the revised version on Thursday.
Within the next sync, the old aid disappears from every rep's library, including the rep presenting offline in a cath lab who picks up the change when she reconnects. The revised version appears in the same folder, under the same name, with a new job code. Nobody sends an email announcement asking reps to "please delete the old version." Marketing can see which reps have opened the new piece. Compliance can answer "who could still show the old one?" with a single word: nobody.
Review time didn't change. Time-to-field went from weeks to hours.
If you want to start somewhere this week, measure two numbers separately for your last ten approved pieces: submission to approval, and approval to first field use. Most teams have never looked at the second number. It is usually the easier one to shrink.
Frequently Asked Questions
How long does MLR review take?
It depends on the piece's risk and the number of review rounds, so the useful number is your own. Track submission-to-approval and approval-to-field separately for recent pieces. Teams that only measure the first number often miss a delay of several weeks in the second.
Is MLR the same as PRC?
Mostly. PRC (promotional review committee) and MLR describe the same cross-functional review of promotional material. Some companies use PRC for the committee and MLR for the three core disciplines on it: medical, legal and regulatory.
Does MLR review apply to medical device companies?
Yes, although device companies often call it promotional or advertising review. FDA regulates device labeling, and restricted-device advertising must include the established name, intended uses and relevant warnings. Device teams run the same medical, legal and regulatory checks that pharma teams do.
What happens to approved content when it expires?
It should leave circulation automatically: out of the field library, out of shared links, and off rep devices. When expiration lives only in the review system, expired pieces stay in reps' downloads and inboxes. The expiry date needs to travel with the file.